Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Generic Of GSK Flonase But Launch Halted By Restraining Order

Executive Summary

FDA's approval of generic Flonase has prompted a lawsuit by GlaxoSmithKline representing another challenge by brand manufacturers to the legitimacy of FDA-approved generic drugs

You may also be interested in...



Industry/Agency Revolving Door Hits Spear In Nose, But Firm Relaunches ANDA

While Spear's generic fluorouracil is back on the market after a temporary restraining order expired June 18, the odyssey illustrates the risks to companies inherent in FDA relying on industry opinions during product review

Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent

FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics

Related Content

UsernamePublicRestriction

Register

PS046911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel